Blog

What we learned at Phoenix UGM at Certainty 2026 about the future of PK/PD

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= 2026年5月8日 At Certainty 2026, the Phoenix User Group Meeting brought together scientists,…

Certara2026年5月8日

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

Certara2026年5月7日

Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

Certara2026年5月7日

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

Certara2026年5月7日

On-Demand Webinar

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

Explore how Phoenix NLME and RsNLME support early phase clinical pharmacology workflows where speed, clarity,…

Certara2026年5月6日

Blog

GxP compliance in the cloud: What IT teams need to rethink

Learn how GxP validation works in modern SaaS and cloud environments, with best practices for…

Certara2026年5月4日

Webinar

ICH M13B Strength Biowaiver

Certara2026年4月28日

Blog

ADC dose optimization: Applying model-informed strategies in development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

Certara2026年4月22日

On-Demand Webinar

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

Learn how model-informed strategies support ADC labeling, dose optimization, and market access through integrated evidence…

Certara2026年4月10日

Webinar

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

Certara2026年4月10日

Powered by Translations.com GlobalLink Web Software

臨床薬理

What we learned at Phoenix UGM at Certainty 2026 about the future of PK/PD

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

GxP compliance in the cloud: What IT teams need to rethink

ICH M13B Strength Biowaiver

ADC dose optimization: Applying model-informed strategies in development

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

メルマガ登録

クイックアクセス

ソリューション

お問合せ